Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Merck
Medtronic
AstraZeneca
Baxter

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LISDEXAMFETAMINE DIMESYLATE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Lisdexamfetamine Dimesylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00500071 Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD Completed Shire Phase 4 2007-07-01 Assess the efficacy & tolerability of Vyvanse when children aged 6-12 years diagnosed with ADHD are dosed to optimal effect.
NCT00500149 A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD) Completed Shire Phase 3 2007-06-01 The primary objective of this study is to assess the time of onset of Vyvanse compared to placebo, in the analog classroom as measured by the Swanson, Kotkin, Agler, M. Flynn and Pelham (SKAMP) deportment scale in children (aged 6-12) diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).
NCT00557011 NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD Completed New River Pharmaceuticals Phase 2 2004-09-01 The purpose of this study is to assess, in a controlled environment, the efficacy and safety of NRP104 and Adderall XR compared to placebo in treatment of children, aged 6-12, with ADHD.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lisdexamfetamine Dimesylate

Condition Name

Condition Name for Lisdexamfetamine Dimesylate
Intervention Trials
ADHD 7
Attention Deficit Hyperactivity Disorder 6
Attention Deficit Disorder With Hyperactivity 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lisdexamfetamine Dimesylate
Intervention Trials
Attention Deficit Disorder with Hyperactivity 22
Disease 11
Hyperkinesis 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lisdexamfetamine Dimesylate

Trials by Country

Trials by Country for Lisdexamfetamine Dimesylate
Location Trials
United States 125
Germany 21
Spain 16
United Kingdom 14
Poland 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lisdexamfetamine Dimesylate
Location Trials
California 9
Texas 8
North Carolina 7
New York 7
Kansas 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lisdexamfetamine Dimesylate

Clinical Trial Phase

Clinical Trial Phase for Lisdexamfetamine Dimesylate
Clinical Trial Phase Trials
Phase 4 12
Phase 3 10
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lisdexamfetamine Dimesylate
Clinical Trial Phase Trials
Completed 20
Recruiting 6
Not yet recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lisdexamfetamine Dimesylate

Sponsor Name

Sponsor Name for Lisdexamfetamine Dimesylate
Sponsor Trials
Shire 22
New York University School of Medicine 2
Yale University 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lisdexamfetamine Dimesylate
Sponsor Trials
Industry 23
Other 18
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Baxter
Colorcon
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.